Intellia Therapeutics Revenue Misses Estimates as GAAP Loss Per Share Hits $0.91

Intellia Therapeutics, Inc. posted a $0.91 GAAP loss per share for the third quarter of 2026, 11 cents worse than analyst estimates, while revenue also missed forecasts. Total revenue came to $7.16 million, $2.61 million below estimates. Separately, collaboration revenue was $7.2 million, down 48% from $13.8 million in the third quarter of 2025. John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

Source: TokenPost